# A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)

> **NCT00927511** · PHASE2 · UNKNOWN · sponsor: **Regina Elena Cancer Institute** · enrollment: 104 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00927511
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2011-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927511, "A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00927511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*